A $428,000 Cell Therapy Just Got FDA Approval. Its Real Cost to the Healthcare System May Be Half That.

On June 30, the FDA approved Tregzi, a donor-derived cellular immunotherapy manufactured by privately held Orca Bio of Menlo Park, California, and the first therapy to use highly purified regulatory T cells in allogeneic hematopoietic stem cell transplantation. Its acquisition cost, $428,000 per treatment as CEO Nate Fernhoff told Reuters, landed like a verdict on healthcare policy: another six-figure cell therapy from a venture-backed biotech, priced beyond what most institutions can absorb without a fight.

But sticker prices lie, and they especially lie in oncology, where the cost of a treatment and the cost to the system are almost never the same number because the most expensive thing in transplant medicine is not what you give patients but what happens to them afterward. Tregzi prevents chronic graft-versus-host disease (cGVHD), a debilitating immune complication that strikes roughly 44% of conventional transplant recipients and generates healthcare bills stretching across years of immunosuppressive therapy, organ damage management, and repeated hospitalizations. I ran the numbers on what the system actually pays when you subtract the catastrophe it prevents.

What Tregzi Actually Does

Allogeneic stem cell transplants are, by a wide margin, among the most brutal procedures in medicine: a patient's bone marrow is obliterated with chemotherapy or radiation, then rebuilt using donor cells whose immune system can either kill residual cancer or attack the patient's own tissues in a condition called graft-versus-host disease. Acute GVHD strikes within weeks; chronic GVHD sets in months later, damaging skin, liver, lungs, and joints, and persists for years as the leading cause of non-relapse mortality among long-term survivors.

Tregzi is built from three cell populations sorted from a matched donor's blood: hematopoietic stem cells to rebuild the marrow, conventional T cells to fight cancer relapse, and purified Tregs to suppress the immune attack causing GVHD. In the PRECISION-T Phase 3 trial (n=187, 19 centers), 78% of Tregzi patients were alive without moderate-to-severe cGVHD at one year, compared with 38% receiving conventional transplants (HR 0.26, p<0.00001). Only 13% developed serious cGVHD versus 44% in the control arm, non-relapse mortality dropped from 13% to 3%, and overall survival reached 94% versus 83%.

Lifetime Cost of the Disease It Prevents

A 2024 analysis in Blood Advances by Maziarz et al. quantified the US payer cost: lifetime per-patient medical expenditure for allo-HCT runs approximately $1.2 million, of which 37% to 53% ($444,000 to $636,000) is consumed by cGVHD management alone, including the immunosuppressive regimens, outpatient visits, rehospitalizations, and disability that accumulate over years of follow-up. With newer oral agents for steroid-refractory cGVHD now in clinical use, the projected lifetime cost climbs to $1.4 to $1.6 million per patient, and a separate study in Supportive Care in Cancer found that all-cause healthcare costs were approximately three times higher among GVHD patients ($295,000 to $313,000 in disability-related costs versus $94,000 to $96,000 without GVHD).

Methodology: System-Level Math

How many patients would be eligible? According to the CIBMTR 2025 annual report, US allo-HCT volume reached roughly 9,500 procedures per year by 2023, recovering strongly from a COVID-era dip. Tregzi's label requires an 8/8 HLA-matched donor (matched related plus matched unrelated donors together comprise 63% of all allo-HCTs), myeloablative conditioning (approximately 50% of adult procedures), and an adult patient with AML, ALL, MDS, or MPAL (roughly 75-80% of adult transplant indications). Multiply through: approximately 2,000 to 2,500 US patients per year meet every criterion simultaneously.

Per 1,000 eligible patients treated under conventional transplant, 440 develop moderate-to-severe cGVHD and 130 die from non-relapse causes within the first year, producing a lifetime cGVHD management burden of approximately $237.6 million at the $540,000 midpoint of Maziarz's cost attribution. Under Tregzi, 130 develop cGVHD and 30 die from non-relapse causes, dropping management costs to $70.2 million while adding $428 million in acquisition costs for 1,000 doses.

Savings from cGVHD prevention: $167 million per 1,000 patients. Reduced readmissions, fewer Grade 3 infections (8.4% vs. 16.1% cumulative incidence), less immunosuppressive therapy, and lower disability costs add a conservative $30 to $50 million. Net additional cost of Tregzi after offsets: roughly $211 million per 1,000 patients, or approximately $211,000 per patient treated, not $428,000.

That $211,000 buys 100 additional survivors per 1,000 treated based on the non-relapse mortality differential, translating to approximately 470 quality-adjusted life years gained at the 4.7-QALY baseline from the Maziarz lifetime model. Cost per QALY: roughly $449,000, squarely within the range of CAR-T therapies like tisagenlecleucel and axicabtagene ciloleucel that carry acquisition costs of $373,000 to $475,000, published cost-per-QALY estimates of $300,000 to $600,000, and payer acceptance already established in clinical practice.

A Strong Counterargument

PRECISION-T compared Tregzi against calcineurin inhibitor/methotrexate prophylaxis, the historical standard, but the transplant field has been sprinting toward post-transplant cyclophosphamide (PTCy) regimens that also substantially reduce GVHD rates. "How the Orca-T approach will fare against PTCy regimens will need to be explored in a future study," wrote Dana-Farber's Robert Soiffer in an editorial accompanying the trial results.

Cyclophosphamide is a generic drug, and CIBMTR data shows PTCy adoption already exceeds 50% in mismatched unrelated donor transplants while climbing rapidly in matched donor settings, so if PTCy delivers 60 to 70% of Tregzi's cGVHD reduction at less than 1% of the cost, the economic case weakens considerably. Tregzi may be launching into a market where its true comparator is not the old standard it beat in the trial but a newer, cheaper standard barely represented in the study it won. Orca Bio would argue that engineered immune tolerance differs fundamentally from chemical T cell depletion, with potential long-term advantages in immune reconstitution and graft-versus-leukemia activity, but that argument has biological plausibility without head-to-head data to support it.

What This Analysis Does Not Prove

PRECISION-T followed patients for one year, and my lifetime cost projections extrapolate from historical models built on 2016-2020 claims data that may not reflect current treatment patterns or drug pricing. If Tregzi's cGVHD prevention erodes beyond the one-year window, savings shrink accordingly. Eligible population estimates depend on conditioning intensity splits that vary considerably by center. And Orca Bio is privately held with cell therapy manufacturing that is notoriously fragile at scale: serving 2,000-plus patients per year commercially will test logistics that worked at trial volume.

What This Means for You

If you are a transplant physician, Tregzi enters your toolkit immediately for 8/8 matched-donor myeloablative transplants in adults, with orders opening by end of July, and you should arm yourself with the net-cost argument in payer negotiations because the acquisition price overstates the economic impact by roughly half when lifetime cGVHD costs are factored in. If you work in health policy, watch for CMS coverage determinations: Tregzi's cost-per-QALY profile is comparable to CAR-T therapies Medicare already covers, and denying coverage on price alone while approving CAR-T would be internally inconsistent. If you are a patient or caregiver facing an allo-HCT decision, ask your transplant team whether your donor match and conditioning regimen make you eligible, because the 70% relative reduction in serious cGVHD, combined with lower infection rates and a non-relapse mortality drop from 13% to 3%, represents some of the strongest randomized trial data in recent transplant medicine.

Tregzi is expensive the way fire insurance is expensive: you notice what you paid, but you rarely calculate what you didn't lose.